Synapse Biomedical has reported positive results from a study conducted on the company’s NeuRx Diaphragm Pacing System (DPS) for spinal cord injuries implants.
In collaboration with six of the Spinal Cord Injury Model System (SCIMS) centres, a long-term follow-up study was conducted on patients with spinal cord injuries implanted with the NeuRx DPS over a course of seven years.
Dr Dan Lammertse of Craig Hospital has reported a satisfactory result from patients using the technology where the implantation of the device was done in one day with the majority of patients being discharged within two days of implantation.
Approved by the US Food and Drug Administration (FDA), the NeuRx DPS is a four-channel, battery-powered neurostimulator with implanted electrodes which is designed to assist spinal cord injury patients to reduce their dependency on mechanical ventilation.
It is a minimally invasive medical outpatient procedure to facilitate a deeper and more comfortable breathing pattern.
The device is comprised of four electrodes implanted in the diaphragm which generates electrical stimulation for the muscle and nerves of the diaphragm.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
A fifth electrode under the skin completes the electrical circuit with a connector holder, a cable and an external battery powered pulse generator.
With spinal cord injury (SCI), the NeuRx DPS provides ventilator support in patients with diaphragm dysfunction of neuromuscular origin.
Diaphragm dysfunction can cause abnormal or absent respiration in patient populations with high-level spinal cord injury and other injuries or diseases disrupting the neuromuscular respiratory pathways.
The NeuRx DPS secured the CE Mark in 2007 and is approved for treating patients with diaphragm dysfunction in the European Union.
It received FDA approval for treating chronic hypoventilation from ALS in 2011.
Image: NeuRx DPS for spinal cord patients. Photo: courtesy of PR Newswire Association LLC.